Table 1 Baseline characteristics of primary Sjögren syndrome (pSS) patients enrolled
Patient | Sex | Age | Disease duration (y, mo) | Anti-SS-A | Anti-SS-B | Biopsy | Therapies | Manifestations | CRP/BSR | ESSDAI score |
|---|---|---|---|---|---|---|---|---|---|---|
pSS 1 | f | 50 | 7mo | 181 | 0.1 | Neg | Artificial tears | Ocular sicca | Normal | 0 |
pSS 2 | f | 43 | 11y 11mo | 240 | 75 | Pos | None | Ocular, oral and vaginal sicca, glandular swelling | Normal | 2 |
pSS 3 | f | 76 | 36y 1mo | 240 | ND | ND | Artificial saliva | Ocular and oral sicca | Normal | 0 |
pSS 4 | f | 48 | 11y 1mo | 240 | 0.1 | ND | CFZ-533 *, hydroxychloroquine | Ocular and oral sicca | ND | 17 |
pSS 5 | f | 65 | Unknown | 131 | 3.2 | ND | ND | ND | ND | ND |
pSS 6 | f | 50 | 2y 2mo | 240 | 5 | Pos | None | Ocular sicca | Normal | 0 |
pSS 7 | m | 40 | 16y 2mo | 240 | ND | Pos | Prednisolone p.o. and i.v., artificial tears | Ocular and oral sicca haematological manif., vasculitis, glandular swelling, pneumonitis | Elevated ESR & Elevated CRP | 34 |
pSS 8 | f | 60 | 6mo | 240 | 320 | ND | None | Ocular and oral sicca | Elevated CRP | 15 |
pSS 9 | f | 60 | 1mo | 240 | 5 | Pos | Artificial tears | Ocular and oral sicca | Normal | 5 |
pSS 10 | f | 30 | 7mo | 5 | 5 | Pos | None | Ocular and oral sicca | Normal | 0 |
pSS 11 | m | 60 | 1y 6mo | 240 | 6 | Pos | None | Ocular and oral sicca | Normal | 1 |
pSS 12 | f | 53 | 3y 1mo | 240 | 320 | Pos | Methotrexate, hydroxychloroquine, artificial saliva | Ocular and oral sicca | Normal | 6 |
pSS 13 | f | 51 | 9mo | 20 | ND | ND | Hydroxychloroquine, artificial tears, artificial saliva | Sicca | Normal | 4 |
pSS 14 | f | 64 | 37y 6mo | 240 | 298 | Pos | Artificial saliva | Ocular and oral sicca | Normal | 3 |
pSS 15 | f | 53 | 10mo | 240 | ND | Pos | Methotrexate, hydroxychloroquine, artificial saliva | Ocular, oral and vaginal sicca | Normal | 8 |